Scribe Therapeutics

We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️‍🩹

Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart...

#HeartDisease #OurHearts #HeartMonth

The Present And Future Of Gene Editing - EP 54 Jennifer Doudna A Nobel Prize-winning pod

🫀 At Scribe we're pioneering highly engineered CRISPR technologies and genetic medicines that leverage nature’s blueprint for better #HeartHealth.

Learn more about gene editing’s present and future from Nobel Prize winner and our co-founder Dr. Doudna: www.corememory.com/p/the-presen...

💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention.

Links ⬇️

Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications.

Episode link 🔗 www.cellandgene.com/doc/building...

Apple Podcasts 🔗 podcasts.apple.com/us/podcast/b...

Spotify 🔗 open.spotify.com/episode/5jM4...

#CGT #GeneEditing #Epigenetics #HeartHealth

How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions?

Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy The company’s lead program is an epigenetic silencing therapy designed to turn off genes without altering the underlying genetic code.

ICYMI learn more in @endpts.com about our plans to enter the clinic in mid-2026 with STX-1150, and our broader work to deliver on the potential of #CRISPR and nature’s blueprint for better cardiovascular health.

endpoints.news/scribe-thera...

#EpigeneticEditing #Epigenetics #HeartHealth #OurHearts

As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease.

STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics.

More in @endpts.com 👇

#ICYMI, read the press release announcing our STX-1150 clinical trial: www.businesswire.com/news/home/20...

Watch the panel at Fierce JPM Week on-demand: www.fiercejpmweek.com/fiercejpmwee...

Another successful JPM is in the books 📕

From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy The company’s lead program is an epigenetic silencing therapy designed to turn off genes without altering the underlying genetic code.

Read about our lead program & leadership leveraging nature’s blueprint for better cardiovascular health: www.businesswire.com/news/home/20...

Manuscript: www.biorxiv.org/content/10.6...

Thanks @scienceboss.bsky.social @endpts.com for covering these latest advances: endpoints.news/scribe-thera...

NEW PREPRINT: Introducing an additional regulatory layer for enhanced precision and potency in #CRISPR-CasX-based epigenetic medicine.

Press release and preprint links below 🧵

#EpigeneticEditing #Epigenetics

“We designed STX-1150 to overcome many of the limitations of today’s lipid-lowering therapies through powerful epigenetic silencing, and to meaningfully change how cardiovascular risk is managed for millions of patients.” – Scribe CEO @benjaminloakes.bsky.social

#CVD #HeartDisease

FROM BENCH TO BEDSIDE: Unveiled at #JPM2026, our plans to enter the clinic in mid-2026 underscore Scribe’s mission to shift cardiovascular care for millions of people – from late, symptom-driven intervention to earlier, durable risk reduction grounded in human genetics.

We're pleased to announce:

📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

Happening TODAY at #JPM2026!

Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT).

#JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Kick off JPM Week with us this Sunday!

Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more.

Details below 🧬👇

For more details about our #JPM26 presentation: www.businesswire.com/news/home/20...

Register to attend Fierce JPM Week:
www.fiercejpmweek.com

Coming up next week at #JPM2026:

Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT!

Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Wishing everyone a Happy New Year!

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results A range of CRISPR gene therapies are taking aim at chronically high cholesterol, reducing the risk of heart disease.

Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease.

Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇

singularityhub.com/2025/11/27/c...

Scribe eyes clinic after CRISPR candidates lower lipids in animals Genetic-medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three programs, all of which were able to reduce cardiovascular risk factors in | ...

ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease.

Article by @megadarren.bsky.social.

Scribe We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease.

Visit scribetx.com to learn more about our work to transform the standard of care for cardiometabolic disease from lifelong symptom management towards effective prevention.

Could a single treatment lower heart disease risk by up to 90%?

At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.

Details about our #JPM26 presentation are in our press release: www.businesswire.com/news/home/20...

Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference.

Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026.

#JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Can AI take the guesswork out of CRISPR? New AI tools promise to speed up and simplify CRISPR experiments, but their real-world impact is still being tested.

Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies.

Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...

Huge thanks to the @awscloud.bsky.social team for the opportunity to participate.

We are excited to continue to showcase how the AI platform capability we’ve built to accelerate and enhance CRISPR therapeutic design also performs at a world-class level on real-world AI challenges.

This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide.

Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!

As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful.

Happy Thanksgiving! 🦃